LeMaitre Vascular, Inc. (LMAT) fair value analysis

Nasdaq · Updated 2026-09-07

LeMaitre Vascular, Inc. is a medical device company that develops, manufactures, and markets vascular access products, vascular interventional tools, and related devices used in vascular surgery and interventional radiology procedures. The company operates globally, with a presence in North America, Europe, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, LMAT is trading at a 10–25% discount to estimated fair value.

LMAT currently ranks #38 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $103.61
Sector: Healthcare
12-month range: $79.78–$111.76

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C+
Leverage: Low
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The upper-middle quarter of its range

What our data shows for LMAT

Our model validated 17 trailing price-to-earnings windows for LMAT, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $79.78–$111.76.
The 14-day relative strength index sits at a neutral 55.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LMAT
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LMAT news

TickrTrends' derived news-sentiment signal for LMAT is currently leaning positive, computed from recent coverage.

Speculative Rally Weighed on LeMaitre Vascular (LMAT) (finance.yahoo.com, 2026-09-01)
TickrTrends take: LeMaitre Vascular operates in the Healthcare sector and is currently assessed as undervalued by TickrTrends valuation metrics. A speculative rally in the stock creates a timing consideration for valuation-focused investors, as such rallies can temporarily inflate prices above intrinsic value levels. Observers of the company should monitor whether the stock's valuation remains attractive after speculative activity subsides or whether price appreciation has narrowed the gap to fair value.
LeMaitre to Participate at Upcoming Investor Conferences in September (manilatimes.net, 2026-08-27)
TickrTrends take: LeMaitre Vascular's participation in investor conferences during September provides an opportunity for the market to reassess the company's growth prospects and strategic direction, which becomes relevant given TickrTrends' current undervalued assessment. For valuation-focused investors, these conferences may offer insights into management's confidence in execution and pipeline developments that could justify whether the current undervalued designation persists. The extent to which LeMaitre can articulate competitive advantages and market expansion opportunities at these events could influence whether its valuation gap compared to peers narrows or widens.
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut (NASDAQ:LMAT) (seekingalpha.com, 2026-08-13)
TickrTrends take: LeMaitre Vascular experienced a significant stock price decline following a minimal guidance reduction, which may have created a disconnect between the severity of the market reaction and the underlying business impact. Given TickrTrends' undervalued assessment, investors focused on valuation metrics should monitor whether the company's fundamentals and earnings power have meaningfully deteriorated or whether the drawdown represents an overreaction in a healthcare sector stock. The extent to which the stock recovers or stabilizes will be important context for evaluating whether the current valuation discount reflects genuine business concerns or presents a potential opportunity.

What people are saying

Follow the LMAT conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for LMAT show a shift in momentum this week, with the Relative Strength Index moving from oversold into neutral territory. This transition suggests reduced downward pressure on the stock following last week's oversold conditions. The current valuation assessment remains Undervalued according to TickrTrends' analysis.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LMAT stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LMAT is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is LMAT's TickrTrends verdict?

LMAT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does LMAT compare to other Healthcare stocks?

LMAT ranks #38 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LMAT overbought or oversold?

LMAT's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LMAT vs ABT · LMAT vs CI · LMAT vs DVA · LMAT vs INCY · LMAT vs MMSI